How can we integrate the biology of breast cancer cell dormancy into clinical practice?

Autor:	Elkholi IE; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada; Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada; Molecular Biology Programs, Université de Montréal, Montreal, QC, Canada. Electronic address: islam.elkholi@mail.mcgill.ca., Rose AAN; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada., Aguirre-Ghiso JA; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA; Cancer Dormancy and Tumor Microenvironment Institute, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA; Ruth L. & David S. Gottesman Institute for Stem Cell Research & Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY, USA; Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY, USA., Côté JF; Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada; Molecular Biology Programs, Université de Montréal, Montreal, QC, Canada; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montreal, QC, Canada; Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada. Electronic address: jean-francois.cote@ircm.qc.ca.
Jazyk:	angličtina
Zdroj:	Cancer cell [Cancer Cell] 2024 Jul 08; Vol. 42 (7), pp. 1147-1151. Date of Electronic Publication: 2024 Jun 20.
DOI:	10.1016/j.ccell.2024.05.023
Abstrakt:	Clinical practice and clinical research heavily rely on primary tumors, circulating tumor DNA, and/or overt metastases as sources of material for predicting or investigating breast cancer metastatic relapses. However, these approaches do not consider emerging fundamentals in the biology of metastatic dormancy and relapse. Conversely, the field of metastatic dormancy often discounts key clinical factors influencing relapse dynamics (e.g., patient's age and overall health condition). Here, we delineate these disparities into four gaps and propose a framework to bridge them. Competing Interests: Declaration of interests A.A.N.R. reports personal fees from Advanced Accelerator Applications/Novartis and EMD Serono in addition to institutional research funding for clinical research from: Bayer, Merck, Pfizer, AstraZeneca, and Seagen. She also reports personal/speaker fees from AstraZeneca. These financial relationships are unrelated to the current manuscript. J.A.A.-G. is a scientific co-founder, scientific advisory board member, and equity owner in HiberCell and receives financial compensation as a consultant for HiberCell, a Mount Sinai spin-off company focused on the research and development of therapeutics that prevent or delay the recurrence of cancer. He is a consultant for Astrin Biosciences, Chief Mission Officer for the Samuel Waxman Cancer Research Foundation, and a member of the advisory board of Cancer Cell. (Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu